These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25630967)

  • 1. New perspectives on type I IFNs in cancer.
    Gajewski TF; Corrales L
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):175-8. PubMed ID: 25630967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature.
    Spaapen RM; Leung MY; Fuertes MB; Kline JP; Zhang L; Zheng Y; Fu YX; Luo X; Cohen KS; Gajewski TF
    J Immunol; 2014 Oct; 193(8):4254-60. PubMed ID: 25217157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The host STING pathway at the interface of cancer and immunity.
    Corrales L; McWhirter SM; Dubensky TW; Gajewski TF
    J Clin Invest; 2016 Jul; 126(7):2404-11. PubMed ID: 27367184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The added value of type I interferons to cytotoxic treatments of cancer.
    Bracci L; Sistigu A; Proietti E; Moschella F
    Cytokine Growth Factor Rev; 2017 Aug; 36():89-97. PubMed ID: 28693974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications.
    Rizza P; Moretti F; Capone I; Belardelli F
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):195-201. PubMed ID: 25466627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Interplay between Type I and II Interferons Is Essential to Limit Influenza A Virus-Induced Tissue Inflammation.
    Stifter SA; Bhattacharyya N; Pillay R; Flórido M; Triccas JA; Britton WJ; Feng CG
    PLoS Pathog; 2016 Jan; 12(1):e1005378. PubMed ID: 26731100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STING pathway agonism as a cancer therapeutic.
    Flood BA; Higgs EF; Li S; Luke JJ; Gajewski TF
    Immunol Rev; 2019 Jul; 290(1):24-38. PubMed ID: 31355488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.
    Ohkuri T; Ghosh A; Kosaka A; Zhu J; Ikeura M; David M; Watkins SC; Sarkar SN; Okada H
    Cancer Immunol Res; 2014 Dec; 2(12):1199-208. PubMed ID: 25300859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I interferon response and innate immune sensing of cancer.
    Fuertes MB; Woo SR; Burnett B; Fu YX; Gajewski TF
    Trends Immunol; 2013 Feb; 34(2):67-73. PubMed ID: 23122052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and utility of innate immune system evasion mechanisms of ASFV.
    Correia S; Ventura S; Parkhouse RM
    Virus Res; 2013 Apr; 173(1):87-100. PubMed ID: 23165138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate immune sensing of cancer: clues from an identified role for type I IFNs.
    Gajewski TF; Fuertes MB; Woo SR
    Cancer Immunol Immunother; 2012 Aug; 61(8):1343-7. PubMed ID: 22722449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-edged effects of interferons on the regulation of cancer-immunity cycle.
    Zhang X; Wang S; Zhu Y; Zhang M; Zhao Y; Yan Z; Wang Q; Li X
    Oncoimmunology; 2021; 10(1):1929005. PubMed ID: 34262796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The STING pathway and the T cell-inflamed tumor microenvironment.
    Woo SR; Corrales L; Gajewski TF
    Trends Immunol; 2015 Apr; 36(4):250-6. PubMed ID: 25758021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.
    Zhu J; Huang X; Yang Y
    J Virol; 2007 Apr; 81(7):3170-80. PubMed ID: 17229689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirally delivered IFN-β exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation.
    Oh SS; Moon C; Kim DH; Song H; Park S; Fu Y; Kim KD
    Int J Mol Med; 2012 Jun; 29(6):1153-7. PubMed ID: 22426464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate immune recognition of cancer.
    Woo SR; Corrales L; Gajewski TF
    Annu Rev Immunol; 2015; 33():445-74. PubMed ID: 25622193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.
    Ferrantini M; Capone I; Belardelli F
    Biochimie; 2007; 89(6-7):884-93. PubMed ID: 17532550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I interferons as regulators of human antigen presenting cell functions.
    Gessani S; Conti L; Del Cornò M; Belardelli F
    Toxins (Basel); 2014 May; 6(6):1696-723. PubMed ID: 24866026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
    Cui J; Chen Y; Wang HY; Wang RF
    Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro and In Vivo Preclinical Effects of Type I IFNs on Gliomas.
    Galani V; Papadatos SS; Alexiou G; Galani A; Kyritsis AP
    J Interferon Cytokine Res; 2017 Apr; 37(4):139-146. PubMed ID: 28387596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.